EN DE
Watch Ernexa Therapeutics Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Ernexa Therapeutics Inc (ERNA) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Ernexa Therapeutics Inc stock $2.28, price $2.01, upside +13.4%, quality 24 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

ET Ernexa Therapeutics Inc logo Thin data Nov 11, 2026

Ernexa Therapeutics Inc

ERNA · US
Fairly valued, weak quality

The stock costs 12% less than our calculation considers fair.

Fair value $2.28 · Fairly valued
Mixed Growth (revenue YoY +755.9 %/yr in USD)
Quality 24/100
High debt
Negative free cash flow
Trails peers (3/8)
Narrow moat 23/100
Thin data
Estimate
Watch Ernexa Therapeutics Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$95,100 $1.83 Fair Value $2.28 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

60‑month range $1.83 – $95,100 · fair‑value band $1.71 – $2.85 · the $2.01 price screens below the $2.28 fair value. As of Nov 11, 2026.

Follow Ernexa Therapeutics in your weekly email

Every Wednesday you see whether Ernexa Therapeutics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease.

Show moreShow less

The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis.

It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Stock analysis

Ernexa Therapeutics Inc (ERNA) currently trades at $2.01, while our estimate is $2.28, so the stock looks roughly fairly valued today (gap 11.8%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.71 (bear) to $2.85 (bull), the price of $2.01 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 24/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Ernexa Therapeutics Inc reported revenue of $0 in FY2025 versus $0 in FY2021. Reported net income was −$14.1M in FY2025.

Key figures

Market cap $3.3M Micro · EPS (TTM) $−13.63 · Dividend yield 0.5% · Return on equity −321% · Return on assets (EBIT) −202% (5-year average) · Revenue (TTM) $1.0K · Revenue growth (YoY) −94.1% · Free cash flow −$7.1M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (medium confidence).

What moves the price

The share trades about 95% below its 52-week high and 10% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 13%, ERNA screens cheaper than that median.

Fair Value

Bear $1.71 Fair Value $2.28 Bull $2.85
Price $2.01 · Upside +13.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 24/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 33
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyCharles Cherington10% owner4,000,000 shares at $0.5000$2.0MFeb 10, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.1% (2019) → −2,693.1% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ERNA, get fair value alerts →

Compare Ernexa Therapeutics Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 24 · Bottom 25%
Fair Value upside +13.4% · Top 25%
Profitability
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) −94.1% · Bottom 25%
Dividend yield (12 months) 0.5% · Below median
Balance sheet
Debt / equity 2.82× · Highest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.39× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)51 · sector 0
FUTURE (revenue growth)0 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)10 · sector 20

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ERNA
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ERNA
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ERNA
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ERNA
argenx SE ARGX $971.55 $908.40 −7% vs ERNA
CSL Limited CSL A$201.68 A$181.40 −10% vs ERNA
Moderna, Inc MRNA $250.83 $158.70 −37% vs ERNA
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ERNA
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ERNA
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ERNA

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Ernexa Therapeutics Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Ernexa Therapeutics Inc Fair Value". https://www.fairvalue-calculator.com/stock/ERNA

Frequently asked questions

Is Ernexa Therapeutics Inc (ERNA) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $2.28 versus a price of $2.01, about +13% upside (fairly valued).
What is the fair value of ERNA?
Our estimate for Ernexa Therapeutics Inc is $2.28 (as of Nov 11, 2026), built from audited fundamentals. The current price: $2.01.
What is the quality score of ERNA?
Ernexa Therapeutics Inc has a Quality Score of 24/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Ernexa Therapeutics Inc (ERNA)?
Our calculated price target is the estimate of $2.28 (as of Nov 11, 2026). Cautious scenario $1.71, optimistic scenario $2.85. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Ernexa Therapeutics Inc stock forecast for 2026?
Our estimate puts fair value at $2.28, about +13% upside versus a price of $2.01 (fairly valued). Cautious scenario $1.71, optimistic scenario $2.85. The calculation is refreshed regularly with new filings.
What is the revenue of Ernexa Therapeutics Inc (ERNA)?
Ernexa Therapeutics Inc reported trailing-twelve-month revenue of about $1.0K (latest available figure, as of Nov 11, 2026).
Does Ernexa Therapeutics Inc pay a dividend?
Ernexa Therapeutics Inc currently shows a dividend yield of 0.48% relative to its recent price (as of Nov 11, 2026).
How much is the dividend of Ernexa Therapeutics Inc (ERNA)?
Ernexa Therapeutics Inc has a dividend yield of 0.5%.
What is the intrinsic value of Ernexa Therapeutics Inc (ERNA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Ernexa Therapeutics Inc it is $2.28 per share (as of Nov 11, 2026), against a price of $2.01.
Is Ernexa Therapeutics Inc stock overvalued or undervalued in 2026?
As of Nov 11, 2026, ERNA trades below its calculated fair value: price $2.01, fair value $2.28, a gap of about +13% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ERNA?
No. The price is what the market pays today ($2.01); the fair value is what the company's own numbers justify ($2.28). For Ernexa Therapeutics Inc the two are $0.2700 per share apart. That gap is exactly why we show both numbers side by side.
How much is Ernexa Therapeutics Inc worth?
The market values Ernexa Therapeutics Inc at about $3.3M (market capitalisation, as of Nov 11, 2026). Per share that is $2.01; our models calculate a fair value of $2.28 per share.
What do the bullish and bearish scenarios say about ERNA?
Our models span a range for Ernexa Therapeutics Inc: cautious scenario $1.71, base $2.28, optimistic $2.85 per share (as of Nov 11, 2026, price $2.01). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Ernexa Therapeutics Inc (ERNA)?
Balance-sheet figures for Ernexa Therapeutics Inc (as of Nov 11, 2026): return on equity −320.7%, debt of 2.82 per unit of equity. They feed the Quality Score of 24/100, which measures business quality independently of the share price.
How far is ERNA from its 52-week high?
Ernexa Therapeutics Inc trades at $2.01, about 95% below its 52-week high of $41.75 and 10% above the low of $1.83 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.28 is for.
Which stocks are comparable to Ernexa Therapeutics Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Ernexa Therapeutics Inc stock attractive at the current price?
The data as of Nov 11, 2026: price $2.01, calculated fair value $2.28 (+13%), Quality Score 24/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Ernexa Therapeutics Inc currently trades 12% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Ernexa Therapeutics Inc (ERNA)?
The closing price on Nov 10, 2026 was $2.01. Our estimate is $2.28, about +13% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Ernexa Therapeutics Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of Ernexa Therapeutics Inc

How large is the market capitalisation of Ernexa Therapeutics Inc (ERNA)?
The market capitalisation of Ernexa Therapeutics Inc is $3.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Ernexa Therapeutics Inc (ERNA)?
Earnings per share at Ernexa Therapeutics Inc are $−13.63. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Ernexa Therapeutics Inc (ERNA)?
The dividend yield of Ernexa Therapeutics Inc is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the return on equity of Ernexa Therapeutics Inc (ERNA)?
The return on equity (ROE) of Ernexa Therapeutics Inc is −321% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Ernexa Therapeutics Inc (ERNA)?
On an EBIT basis the return on assets of Ernexa Therapeutics Inc is −202% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How fast is revenue growing at Ernexa Therapeutics Inc (ERNA)?
Revenue at Ernexa Therapeutics Inc is growing −94.1% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Ernexa Therapeutics Inc (ERNA) generate?
The free cash flow of Ernexa Therapeutics Inc is −$7.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Ernexa Therapeutics Inc (ERNA) hold?
Ernexa Therapeutics Inc holds more cash than debt, $1.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Ernexa Therapeutics Inc in the live analysis

One click puts Ernexa Therapeutics Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.